Core Insights - 康为世纪 is a leading provider of molecular detection solutions in China, established in 2010 and listed on the Shanghai Stock Exchange in 2022 [1] Financial Performance - In Q3 2025, 康为世纪 reported revenue of 140 million yuan, ranking 36th among 39 companies in the industry, with the industry leader generating 3.428 billion yuan [2] - The company's net profit for the same period was -78.1 million yuan, placing it 31st in the industry, while the top performer reported a net profit of 1.588 billion yuan [2] Profitability and Debt - 康为世纪's debt-to-asset ratio was 9.14% in Q3 2025, lower than the industry average of 18.29% [3] - The gross profit margin for the company was 49.78%, which is below the industry average of 56.20% [3] Shareholder Information - As of September 30, 2025, the number of A-share shareholders decreased by 1.11% to 3,905, while the average number of circulating A-shares held per shareholder increased by 1.13% to 9,729.41 [5] - The largest circulating shareholder, 融通健康产业灵活配置混合A/B, reduced its holdings by 1 million shares [5] Executive Compensation - The chairman and general manager, 王春香, received a salary of 1.205 million yuan in 2024, a decrease of 160,000 yuan from 2023 [4]